糖抗原125(CA125)多克隆抗體
Polyclonal Antibody to Carbohydrate Antigen 125 (CA125)
MUC16; Cancer Antigen 125; Mucin 16,Cell Surface Associated; Ovarian Cancer-Related Tumor Marker CA125; Ovarian Carcinoma Antigen CA125
- 編號PAA154Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPA154Mu01-糖抗原125(CA125)重組蛋白
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有0.02% NaN3和50%甘油)
- 性狀液體
- 濃度0.5mg/mL
- 且適物種Homo sapiens (Human,人)
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術,請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 583 ¥ 1361 ¥ 1944 ¥ 4860 ¥ 19440
- 欲了解實際交易價格和更多情況,請與當地經銷商聯系!
特異性
該抗體是針對CA125的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別CA125。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩定性
熱穩定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產生。保質期內,在適當的條件下存儲,損失率低于5%。
贈品
增值服務
相關產品
編號 | 適用物種:Mus musculus (Mouse,小鼠) | 應用(僅供研究使用,不用于臨床診斷!) |
RPA154Mu01 | 糖抗原125(CA125)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA154Mu02 | 糖抗原125(CA125)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA154Mu01 | 糖抗原125(CA125)多克隆抗體 | WB; IHC; ICC; IP. |
PAA154Mu02 | 糖抗原125(CA125)多克隆抗體 | WB; IHC; ICC; IP. |
LAA154Mu71 | 糖抗原125(CA125)多克隆抗體(生物素標記) | WB; IHC; ICC. |
SEA154Mu | 糖抗原125(CA125)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA154Mu | 糖抗原125(CA125)等多因子檢測試劑盒(流式熒光發光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
PLoS One | Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice. [pubmed:27755542] |
Tumor Biology | KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis [pubmed:28651492] |
Oncotarget | Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer [Pubmed:29484129] |
Prognostic value of STC1 expression in ovarian cancer [] | |
American Journal of Translational Research | Synergistic effect of Tripterygium glycosides and cisplatin on drug-resistant human epithelial ovarian cancer via ILK/GSK3β/Slug signal pathway [Pubmed:35422913] |
留言咨詢